126 related articles for article (PubMed ID: 10155593)
1. Economic evaluation of lenograstim (glycosylated rHuG-CSF) in the treatment of inflammatory breast cancer for Germany and Italy.
Mapelli V; Graf vond der Schulenburg JM; Laaser U; Allhoff PG; Rossi F
Pharmacoeconomics; 1994; 6 Suppl 2():27-35. PubMed ID: 10155593
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
Souêtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic evaluation of lenograstim. Conclusions and future directions.
Menzin J; Oster G; Cour-Chabernaud V; Richard D
Pharmacoeconomics; 1994; 6 Suppl 2():53-60. PubMed ID: 10155595
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
Drummond M; Davies L
Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
[TBL] [Abstract][Full Text] [Related]
5. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Chevallier B; Chollet P; Merrouche Y; Roche H; Fumoleau P; Kerbrat P; Genot JY; Fargeot P; Olivier JP; Fizames C
J Clin Oncol; 1995 Jul; 13(7):1564-71. PubMed ID: 7541448
[TBL] [Abstract][Full Text] [Related]
6. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefits of lenograstim in patients with neutropenia due to chemotherapy for multiple myeloma (MM).
Takagi T; Sawamura M; Sezaki T; Kashimura M; Tsuchiya J; Hotta T; Ogawa N; Hirashima K
Support Care Cancer; 2001 Jul; 9(5):397-9. PubMed ID: 11497396
[TBL] [Abstract][Full Text] [Related]
8. Overview of the lenograstim pharmacoeconomics programme.
Oster G; Menzin J; Richard D; Cour-Chabernaud V
Pharmacoeconomics; 1994; 6 Suppl 2():9-17. PubMed ID: 10155596
[TBL] [Abstract][Full Text] [Related]
9. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K; Matthews J; Young G; Lowenthal R; Baxter H; Arthur C; Bashford J; Brighton T; Cannell P; Dunlop L; Durrant S; Enno A; Eliadis P; Gill D; Gillett A; Gottlieb D; Januszewicz H; Joshua D; Leahy M; Schwarer A; Taylor K;
Leukemia; 2001 Sep; 15(9):1331-8. PubMed ID: 11516093
[TBL] [Abstract][Full Text] [Related]
10. Methodological issues in economic assessments of new therapies. The case of colony-stimulating factors.
Drummond M; Menzin J; Oster G
Pharmacoeconomics; 1994; 6 Suppl 2():18-26. PubMed ID: 10155592
[TBL] [Abstract][Full Text] [Related]
11. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
[TBL] [Abstract][Full Text] [Related]
12. Cost comparison of outpatient treatment with granulocyte colony-stimulating factors (G-CSF) in Germany.
Hadji P; Kostev K; Schröder-Bernhardi D; Ziller V
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):281-9. PubMed ID: 22456299
[TBL] [Abstract][Full Text] [Related]
13. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
[TBL] [Abstract][Full Text] [Related]
14. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
[TBL] [Abstract][Full Text] [Related]
15. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
Bissett D; Jodrell D; Harnett AN; Habeshaw T; Kaye SB; Evans D; Williams M; Canney PA
Br J Cancer; 1995 Jun; 71(6):1279-82. PubMed ID: 7540038
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
[TBL] [Abstract][Full Text] [Related]
20. Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Hüttmann A; Schirsafi K; Seeber S; Bojko P
J Cancer Res Clin Oncol; 2005 Mar; 131(3):152-6. PubMed ID: 15583936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]